Next Article in Journal
Interaction between Rho GTPases and 14-3-3 Proteins
Next Article in Special Issue
Oncomirs Expression Profiling in Uterine Leiomyosarcoma Cells
Previous Article in Journal
Molecular Characterization and Functional Analysis of a Ferritin Heavy Chain Subunit from the Eri-Silkworm, Samia cynthia ricini
Previous Article in Special Issue
Prediction Potential of Serum miR-155 and miR-24 for Relapsing Early Breast Cancer
Article Menu
Issue 10 (October) cover image

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2017, 18(10), 2136; https://doi.org/10.3390/ijms18102136

Plasma miR-155, miR-203, and miR-205 are Biomarkers for Monitoring of Primary Cutaneous T-Cell Lymphomas

1
BIOCEV, First Faculty of Medicine, Charles University, 25250 Vestec, Czech Republic
2
Institute of Pathological Physiology, First Faculty of Medicine, Charles University, 12853 Prague, Czech Republic
3
Department of Haematology, First Faculty of Medicine, Charles University and General Hospital, 12808 Prague, Czech Republic
4
Department of Dermatology and Venereology, First Faculty of Medicine, Charles University and General Hospital, 12808 Prague, Czech Republic
5
Faculty of Mathematics and Physics, Charles University, 18675 Prague, Czech Republic
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Received: 31 August 2017 / Revised: 26 September 2017 / Accepted: 4 October 2017 / Published: 15 October 2017
View Full-Text   |   Download PDF [4021 KB, uploaded 15 October 2017]   |  

Abstract

Primary cutaneous T-cell lymphomas (CTCL) affect the skin and tend to transform and spread. CTCL involves primarily the Mycosis fungoides (MF) and more aggressive Sezary syndrome (SS). Oncogenic microRNAs (miRs) are stable epigenetic inhibitors often deregulated in the tumour and detectable as biomarkers in non-cellular fractions of peripheral blood. The tumour-specific expression of miR-155, miR-203, and miR-205 was shown to correctly diagnose CTCL. We herein asked whether these microRNAs can be used as plasma biomarkers for clinical CTCL monitoring. Patients with CTCL (n = 10) and controls with non-malignant conditions (n = 11) repeatedly donated plasma samples every ca. five months. MicroRNAs were detected in the plasma samples by specifically-primed RT-PCR followed by multivariate analyses of the miR expression dynamics. We herein established the plasma miR-classifier for detecting CTCL based on the miR-155 upregulation and miR-203/miR-205 downregulation with 100% specificity and 94% sensitivity. The 3-miR-score in the consecutive samples coincided with the clinical outcome of MF and SS patients such as the therapy response or changes in the clinical stage or tumor size. Quantitation of the selected microRNAs in plasma is a specific and straightforward approach for evaluating CTCL outcome representing, thus, a valuable tool for CTCL diagnostics and therapy response monitoring. View Full-Text
Keywords: cutaneous T-cell lymphomas (CTCL); mycosis fungoides; Sezary syndrome; microRNA; Psoriasis vulgaris; atopic dermatitis cutaneous T-cell lymphomas (CTCL); mycosis fungoides; Sezary syndrome; microRNA; Psoriasis vulgaris; atopic dermatitis
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Supplementary material

SciFeed

Share & Cite This Article

MDPI and ACS Style

Dusílková, N.; Bašová, P.; Polívka, J.; Kodet, O.; Kulvait, V.; Pešta, M.; Trněný, M.; Stopka, T. Plasma miR-155, miR-203, and miR-205 are Biomarkers for Monitoring of Primary Cutaneous T-Cell Lymphomas. Int. J. Mol. Sci. 2017, 18, 2136.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top